英国精神药理学协会与全国精神重症监护与低安全度病房协会急性激越管理联合循证共识指南:降级干预与快速镇静
该指南由英国精神药理学协会与全国精神重症监护与低安全度病房协会联合制定,针对急性激越的临床管理提供循证推荐和按给药途径与证据类别分层的治疗算法。核心原则包括治疗原发病,并聚焦降级干预、快速镇静前药物干预和快速镇静(肌注与静注)三项关键干预。证据主要来自急诊精神科或急性精神科成人住院环境,也涉及综合急性医院和司法精神病学。指南指出可选药物超出劳拉西泮、氟哌啶醇和异丙嗪的标准选择,包括口服吸入洛沙平、颊黏膜咪达唑仑、多种口服抗精神病药,以及肌注阿立哌唑、肌注氟哌利多和肌注奥氮平;静注选项仅限具备复苏设备和受训人员处理医疗紧急情况的环境。
要点
- 急性激越管理应首先治疗原发病,并强调降级干预作为核心非药物措施。
- 快速镇静前药物干预和快速镇静(肌注与静注)是三项关键干预之一,静注选项仅在具备复苏设备和受训人员处理医疗紧急情况的环境中使用。
- 可选药物超出劳拉西泮、氟哌啶醇和异丙嗪的标准选择,包括口服吸入洛沙平、颊黏膜咪达唑仑及多种口服抗精神病药。
- 肌注选项包括阿立哌唑、氟哌利多和奥氮平;静注选项需在能处理医疗紧急情况的环境中使用。
- 证据主要来自急诊精神科或急性精神科成人住院环境,也涉及综合急性医院和司法精神病学。
适用人群与场景
- 证据主要涉及急诊精神科护理或急性精神科成人住院护理,也涉及综合急性医院和司法精神病学等其他常见临床环境。
处置流程与药物剂量
- 核心原则包括治疗原发病,并聚焦降级干预、快速镇静前药物干预和快速镇静(肌注与静注)三项关键干预。
- 药物选择超出劳拉西泮、氟哌啶醇和异丙嗪的标准选择,包括口服吸入洛沙平、颊黏膜咪达唑仑以及多种口服抗精神病药。
- 胃肠外选项包括肌注阿立哌唑、肌注氟哌利多和肌注奥氮平。
- 静注选项仅用于具备复苏设备和受训人员处理医疗紧急情况的环境。
研究设计与关键结果
- 该指南由英国精神药理学协会与全国精神重症监护与低安全度病房协会联合制定,采用循证共识方法,推荐按给药途径和证据类别分层,并附治疗算法。
证据类型、等级与局限
- 证据类型:英国精神药理学协会与全国精神重症监护与低安全度病房协会联合循证共识指南。
- 局限:原文未报告局限性。
对床旁实践的改变
- 急性激越管理不应仅限于劳拉西泮、氟哌啶醇和异丙嗪,可考虑口服吸入洛沙平、颊黏膜咪达唑仑、多种口服抗精神病药以及肌注阿立哌唑、肌注氟哌利多和肌注奥氮平。
- 静注选项仅在具备复苏设备和受训人员处理医疗紧急情况的环境中使用。
- 应首先治疗原发病,并优先采用降级干预。
指南或共识出处
- Joint BAP NAPICU evidence-based consensus guidelines for the clinical management of acute disturbance: De-escalation and rapid tranquillisation(英国精神药理学协会与全国精神重症监护与低安全度病房协会联合循证共识指南,发表于 J Psychopharmacol)
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
The British Association for Psychopharmacology and the National Association of Psychiatric Intensive Care and Low Secure Units developed this joint evidence-based consensus guideline for the clinical management of acute disturbance. It includes recommendations for clinical practice and an algorithm to guide treatment by healthcare professionals with various options outlined according to their route of administration and category of evidence. Fundamental overarching principles are included and highlight the importance of treating the underlying disorder. There is a focus on three key interventions: de-escalation, pharmacological interventions pre-rapid tranquillisation and rapid tranquillisation (intramuscular and intravenous). Most of the evidence reviewed relates to emergency psychiatric care or acute psychiatric adult inpatient care, although we also sought evidence relevant to other common clinical settings including the general acute hospital and forensic psychiatry. We conclude that the variety of options available for the management of acute disturbance goes beyond the standard choices of lorazepam, haloperidol and promethazine and includes oral-inhaled loxapine, buccal midazolam, as well as a number of oral antipsychotics in addition to parenteral options of intramuscular aripiprazole, intramuscular droperidol and intramuscular olanzapine. Intravenous options, for settings where resuscitation equipment and trained staff are available to manage medical emergencies, are also included.
参考来源
- Patel MX, Sethi FN, Barnes TR, et al. Joint BAP NAPICU evidence-based consensus guidelines for the clinical management of acute disturbance: De-escalation and rapid tranquillisation. J Psychopharmacol. 2018. PMID: 29882463. doi:10.1177/0269881118776738
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。